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The precise phenotype and biology of acute myeloid leukemia stemcells remain controversial, in part because the “gold standard”immunodeficient mouse engraftment assay fails in a significant frac-
tion of patients and identifies multiple cell-types in others. We sought to
analyze the clinical utility of a novel assay for putative leukemia stem cells
in a large prospective cohort. The leukemic clone’s most primitive
hematopoietic cellular phenotype was prospectively identified in 109
newly-diagnosed acute myeloid leukemia patients, and analyzed against
clinical risk groups and outcomes. Most (80/109) patients harbored
CD34+CD38– leukemia cells. The CD34+CD38– leukemia cells in 47 of the
80 patients displayed intermediate aldehyde dehydrogenase expression,
while normal CD34+CD38– hematopoietic stem cells expressed high levels
of aldehyde dehydrogenase. In the other 33/80 patients, the CD34+CD38–
leukemia cells exhibited high aldehyde dehydrogenase activity, and most
(28/33, 85%) harbored poor-risk cytogenetics or FMS-like tyrosine kinase 3
internal tandem translocations. No CD34+ leukemia cells could be detected
in 28/109 patients, including 14/21 patients with nucleophosmin-1 muta-
tions and 6/7 acute promyelocytic leukemia patients.  The patients with
CD34+CD38– leukemia cells with high aldehyde dehydrogenase activity
manifested a significantly lower complete remission rate, as well as poorer
event-free and overall survivals. The leukemic clone’s most immature phe-
notype was heterogeneous with respect to CD34, CD38, and ALDH
expression, but correlated with acute myeloid leukemia risk groups and
outcomes. The strong clinical correlations suggest that the most immature
phenotype detectable in the leukemia might serve as a biomarker for “clin-
ically-relevant” leukemia stem cells. ClinicalTrials.gov: NCT01349972.
ABSTRACT
Introduction
More than two decades ago, Lapidot et al. reported that acute myeloid leukemia
(AML) cells capable of engrafting immunodeficient mice expressed a CD34+CD38– nor-
mal hematopoietic stem cell (HSC) phenotype.1 These so-called leukemia stem cells
(LSCs) gave rise to partially differentiated progeny that constituted the bulk of the
leukemia, but possessed only limited proliferative potential.2 More recently, leukemic
cells of varying surface phenotypes, even within the same patient, have been shown to
be capable of engrafting immunodeficient mice, the generally accepted “gold standard”
for LSC activity.3,4 However, this traditional approach for LSC identification has proven
to be somewhat elusive. Not only is the assay cumbersome and non-quantitative,5 but
in a significant fraction of AML patients no leukemia cell sub-
set will engraft5-10 even using the newer mouse models.11 This
inability to confirm the identity of LSCs in many patients is
at least in part the reason that the clinical relevance of LSCs
remains uncertain.12 
Regardless of their tumorigenic potential in immunodefi-
cient mice, leukemic cells that persist after therapy [i.e. min-
imal residual disease (MRD)] are arguably the most clinically
important.13,14 We recently showed that MRD during com-
plete remission (CR) was enriched for CD34+CD38– leukemic
cells, and their presence after therapy was highly associated
with subsequent clinical relapse.13 Others found that
CD34+CD38– leukemia cell frequency correlated with prog-
nosis.7,15 Thus, accumulating evidence now suggests that ini-
tial clinical responses likely reflect the behavior of the bulk
leukemia, while long-term survival/cure requires the eradica-
tion of LSCs.7,13-15 We also showed that the leukemic
CD34+CD38– cells from most patients, particularly those
with core-binding factor (CBF) AMLs, could be separated
from normal HSCs by their expression of aldehyde dehydro-
genase 1 (ALDH). Normal HSCs exhibited high ALDH
expression (CD34+CD38–ALDHhigh), while the putative LSCs
expressed intermediate levels (CD34+CD38–ALDHint).13 These
findings have recently been confirmed.16,17
Clinical outcomes in AML are highly diverse with some
patients curable with standard therapies, others initially
refractory to all known therapies, and the majority eventually
relapsing and succumbing to the disease after initially achiev-
ing CRs. While patient factors such as age and performance
status may influence the heterogeneous outcomes, the
underlying biology - currently best reflected by cytogenetic
and molecular markers - is the major determinant. AML’s
highly diverse biology suggests that the LSCs are also hetero-
geneous. Accordingly, our previous report identified two
patients, both primary refractory to induction, whose puta-
tive LSCs demonstrated high ALDH expression indistin-
guishable from normal HSCs.13 We could not detect any
CD34+ leukemia cells in two other patients.13 Other groups
have also described heterogeneous CD34 and ALDH expres-
sion in AMLs.8,16-20
Since no leukemia subset from many patients will engraft
immunodeficient mice,5-11 and no leukemic CD34+CD38–
cells can be identified in some patients,4,13,15,16,21 other means
for LSC identification are needed to allow for their study clin-
ically.14 Based on our smaller study of mostly CBF AML
patients,13 we hypothesized that the most primitive
hematopoietic cell phenotype that could be found in
leukemia cells might have important clinical relevance. Thus,
we prospectively assessed the leukemia’s most immature
phenotype in a multi-institutional randomized clinical trial
comparing two induction therapies in patients lacking favor-
able-risk cytogenetics: standard cytarabine-based “7+3" ther-
apy22 and a novel regimen called FLAM (flavopiridol, cytara-
bine, mitoxantrone).23,24 To fully assess heterogeneity of the
leukemic clone’s most immature phenotype, we also studied
patients who initially agreed to the trial but were ultimately
ineligible because they were found to have favorable-risk
cytogenetics. Here we find that the most primitive
hematopoietic cellular phenotype present in leukemia cells is
not only heterogeneous for CD34, CD38, and ALDH expres-
sion, but also that this phenotypic heterogeneity correlates
with both AML risk groups and outcomes. Moreover, the
robust clinical correlations suggest that the most immature
phenotype detectable in the leukemia might serve as a bio-
marker for “clinically-relevant” LSCs. 
Methods
Patients
Patients aged 18-70 with newly-diagnosed AML, excluding CBF
AMLs and APL, were eligible for this multicenter clinical study (clin-
icaltrials.gov NCT01349972).24 Patients were randomized 2:1 to
FLAM or the standard “7+3” regimens, respectively.24 Patients who
achieved complete or partial responses to the first cycle were eligible
to receive a second cycle of FLAM or high-dose cytarabine (HiDAC),
and/or could undergo allogeneic bone marrow transplantation
(alloBMT) as per physician discretion. Johns Hopkins patients who
were study ineligible because their cytogenetics proved favorable
were also included in this analysis. Informed consent for participa-
tion in NCT01349972, as well as for the bone marrow donations by
the patients not treated on trial, was obtained in accordance with the
Declaration of Helsinki as approved by the Johns Hopkins
Institutional Review Board.  
Isolation of cells
Specimens were collected between April 2011 and April 2013.
Marrow mononuclear (MMNC) and CD34+ cell subsets were iden-
tified and isolated as previously described.13,25 At least 500,000 cells
from each AML specimen were then stained with Aldefluor
(Aldagen, Durham, NC, USA) to assess ALDH activity according to
the manufacturer’s instructions utilizing diethylaminobenzaldehyde
(DEAB) controls. Next, cells were labeled with monoclonal phyco-
erythrin-conjugated anti-CD34 and allophycocyanin 
(APC)-conjugated anti-CD38 (BD Biosciences, San Jose, CA, USA)
and analyzed with a MoFlo cell sorter (Beckman Coulter, Brea, CA,
USA). Gating for CD34 and CD38 populations was based on clearly
distinguishable populations, or in the absence of such, the negative
antibody control.25 A representative example of gating is shown in
Online Supplementary Figure S1.
Fluorescence in situ hybridization (FISH) and molecular
analyses
For patients with cytogenetic abnormalities detectable by FISH,
250-1000 cell aliquots were sorted directly onto slides and fixed with
3:1 methanol-glacial acetic acid (Sigma-Aldrich, St. Louis, MO,
USA). FISH was performed and analyzed by the Johns Hopkins
Kimmel Cancer Center Cytogenetics Core, using probes specific for
the patients’ known cytogenetic abnormalities per manufacturer’s
guidelines (Abbot Molecular, Des Plaines, IL, USA) as we previously
described.13 Real-time polymerase chain reaction for FLT3 internal
tandem duplication (ITD) (qPCR) and NPM1 mutations (reverse
transcriptase-qPCR) was performed by Johns Hopkins Molecular
Hematopathology Laboratory.
Data analysis
The AML’s most immature phenotype was scored in a blinded
fashion by RJJ, BP, and SM as we previously described.13 Any differ-
ences in scoring were to be decided by a simple majority, but there
was complete concordance on all observations. The samples were
then de-identified by the Johns Hopkins Kimmel Cancer Center
Specimen Accessioning Core for statistical analysis. Clinical out-
comes were determined by the NCT01349972 clinical study team24
blinded to the AML phenotypic data. Event-free survival (EFS) was
defined as the date of treatment to the occurrence of persistent
AML, relapse, or death. Poor-risk cytogenetics [> 3 clonal abnormal-
ities, -5, 5q-, -7, -7q, t(3;3), inv 3, non-t(9;11) 11q23 excluding t(6;9),
t(9;22)] and molecular abnormalities (FLT3-ITD mutation) were clas-
sified according to the European LeukemiaNet reporting system.26
Statistical analysis
P-values for differences in categorical data were determined by
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Fisher’s exact tests or T-tests, and for differences in outcome, strati-
fied by treatment arm (FLAM vs. 7+3), by Mantel-Haenszel tests.
Overall survival (OS) and EFS were estimated using the Kaplan-
Meier method. Differences in OS and EFS according to the leukemic
clone’s most primitive hematopoietic cellular phenotypes were ana-
lyzed with hazard ratios (HR) from Cox proportional hazards mod-
els that adjust for treatment arm, and tested for significance using
likelihood ratio tests.  Analyses were completed using R version
3.1.1.27
Results
Patient characteristics
The leukemia clone’s most primitive hematopoietic cellu-
lar phenotype was assessed in all patients entered in
NCT0134997224 with adequate bone marrow specimens for
analyses. Of the 147 patients entered in the clinical trial, bone
marrow samples from 98 patients were analyzed. The main
reason for patients not being analyzed was the absence of a
research sample because not enough cells could be obtained
with the diagnostic marrow (43 patients). The specimen
arrived in the laboratory but was not adequate for analysis in
4 patients, and consent for the laboratory study was with-
drawn in 2 patients. Over the same time frame, seven
patients with CBF AML and 14 with APL were newly diag-
nosed and treated at Johns Hopkins. Bone marrow samples
from 4 of the CBF patients and 7 of the APL patients were
available for analysis. The clinical characteristics of the 98
patients on trial and the 11 favorable-risk patients not eligible
for the trial are shown in Table 1. 
The leukemia’s most immature phenotype was 
heterogeneous
We defined the most immature phenotype present in the
AML based on CD34, CD38, and ALDH expression, as we
previously described.25,28,29 As CD34+CD38–ALDHhigh
HSCs16,28,30 differentiate into more committed progenitors,
both CD34 and ALDH expression decrease while CD38
expression increases.29,31-33 Thus, CD34+CD38-ALDHint,
CD34+CD38+,  and CD34- cells were considered increasingly
more differentiated phenotypes. The leukemic versus normal
origin of the hematopoietic phenotypes was determined by
cytogenetic (FISH) or molecular (FLT3-ITD or NPM1) mark-
ers when present. 
CD34+ cells comprised a median of 12% (range 0.07 - 81%)
of total MMNCs from the 98 patients in NCT01349972. In
22/98 of the patients, the AML phenotype was clinically
determined to be CD34- by standard flow cytometry crite-
ria:7,16,34 i.e., CD34+ cells represented 
< 1% of the MMNCs (Table 1, Online Supplementary Figure
S2A). In all 22 patients with < 1% CD34+ cells in the
MMNCs, the small fraction (mean + SEM - 0.52+0.08) of
CD34+ cells was completely CD38-ALDHhigh (Table 2, Figure
1A), and displayed low forward (FSC) and side (SSC) scatter
on flow cytometry (data not shown). Only a small percentage
(2.2+1.6%) of the CD34+CD38-ALDHhigh cells contained the
leukemia-specific marker present in the five CD34–
leukemias with cytogenetics detectable by FISH (Table 2).
Likewise, when an AML with < 1% CD34+ cells was FLT3-
ITD or NPM1-mutated (14/22 patients), the CD34+ cells did
not harbor the mutation (Figure 1B).  
CD34+ cells comprised a mean of 25.3+3.1% of MMNCs
in the 76 patients from NCT01349972 who harbored CD34+
leukemia cells; the CD34+CD38– cells comprised 44.8+3.4%
of the CD34+ cells in these patients. In 43 of these 76 patients,
the majority (65.1+3.4%) of CD34+CD38–cells were ALDHint
(Table 2, Online Supplementary Figure S2B), while the ALDHhigh
population represented 1.7+0.5% of the CD34+CD38– cells
(Figure 2A, Table 2). In the 11/43 cases with leukemia-specific
cytogenetics scorable by FISH, we confirmed that the
CD34+CD38–ALDHint cells were predominantly leukemic
(Table 2). In contrast, the small number of
CD34+CD38–ALDHhigh cells predominantly lacked the FISH
marker that characterized the leukemia (Table 2). Likewise,
when AMLs with prominent CD34+CD38–ALDHint popula-
tions exhibited FLT3-ITD mutations (3 patients) or were
NPM1-mutated (4 cases), the CD34+CD38–ALDHint cells
exhibited the mutation while the CD34+CD38–ALDHhigh cells
did not (Figure 2B). The CD34+CD38–ALDHhigh HSCs exhib-
ited much lower FSC (data not shown) and SSC than the
CD34+CD38–ALDHint AML cells (Figure 2A). These data are
consistent with the CD34+CD38–ALDHhigh cells representing
normal HSCs as we previously demonstrated.13 The 4 CBF
patients also displayed prominent leukemic CD34+CD38–
ALDHint populations harboring, and small CD34+CD38–
ALDHhigh fractions lacking, the FISH abnormality (Tables 1, 2).
Only ALDHhigh CD34+CD38– cells were present in 26 of the
76 patients in NCT01349972 with > 1% CD34+ cells (Tables
1, 2 and Figure 3A). In the 14 patients with leukemia-specific
mutations scorable by FISH, the CD34+CD38–ALDHhigh pop-
ulation contained mostly (78+6.7%) leukemic cells (Table 2).
Similarly, this population was mostly leukemic in those
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Figure 1. Assessment of CD34+ cells
from an NPM1 and FLT3-ITD mutat-
ed AML patient with < 1% CD34+
cells. (A) Representative flow cyto-
metric staining pattern of ALDH
activity by CD34 is displayed on
MMNCs from patient. All the CD34+
cells are CD34+CD38–ALDHhigh. The
CD34+ALDHhigh cells are shown in
rectangle. (B) FLT3-ITD status of iso-
lated cell fractions. The CD34– blasts
harbored the FLT3-ITD mutation,
while the CD34+ cells exclusively dis-
played the 330bp wild-type gene. 
A B
patients with AML-specific mutations (6 patients with FLT3-
ITD and 2 with NPM1 mutations) (Figure 3B). The
CD34+CD38–ALDHhigh leukemia cell population contained
many more cells, and also exhibited much higher FSC (data
not shown) and SSC on flow cytometry, than
CD34+CD38–ALDHhigh HSC populations (Figure 2A) as others
have also found.7 In 7 of the 76 patients with CD34+ AML
cells, two nearly equal-sized (or dual) CD34+CD38–ALDHint
(34.4+3.3 of CD34+CD38-cells) and CD34+CD38–ALDHhigh
(40.2+5.2% of CD34+CD38– cells) populations were seen
(Figure 3C, Tables 1, 2). Adequate numbers of cells were sort-
ed for FISH in 4 of these 7 patients, and both the
CD34+CD38–ALDHint andCD34+CD38–ALDHhigh populations
were leukemic (Table 2).
J.M. Gerber et al.
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Table 1. Clinical characteristics of patients studied. Clinical Trial NCT01349972 Patients.
Patient Total (%) CD34– CD34+CD38–ALDHint CD34+CD38–ALDHhigh Dual ALDHhigh & ALDHint
characteristics (n=98) (n=22) (n=43) (n=26)      (n=7)
Median Age 60 (Range: 29-70) 58 (Range: 31-70) 62 (Range: 30-70) 60 (Range: 32-70) 58 (Range: 29-65)
Male 50 (51%) 9 (41%) 25 (58%) 14 (54%) 2 (29%)
WBC>50,000/mm3 9 (9%) 2 (9%) 4 (9%) 2 (8%) 1 (14%)
Adverse Cytogenetics 41 (42%) 1 (5%) 14 (33%) 17 (65%) 7 (100%)
Complex Karyotype 29 (30%) 1 (5%) 9 (21%) 14 (54%) 4 (57%)
Monosomal Karyotype 23 (23%) 0 5 (12%) 14 (54%) 3 (43%)
FLT3-ITD mutation 9 (9%) 3 (14%) 3 (7%) 6 (23%) 0
NPM1 mutation 22 (22%) 14 (64%) 6 (14%) 2 (8%) 0
Secondary AML (prior MDS or MPN) 39 (40%) 5 (23%) 16 (37%) 15 (58%) 3 (43%)
Treatment-related 10 (10%) 2 (9%) 4 (9%) 4 (15%) 0
Favorable-risk 12 (12%) 10 (45%) 2 (5%) 0 0
Intermediate-1 risk 30 (31%) 7 (32%) 15 (35%) 8 (31%) 0
Intermediate-2 risk 18 (18%) 3 (14%) 14 (33%) 1 (4%) 0
Adverse-risk 38 (39%) 1 (5%) 14 (33%) 17 (65%) 7 (100%)
FLAM 69 (70%) 16 (73%) 29 (67%) 19 (73%) 5 (71%)
7+3 29 (30%) 6 (27%) 14 (33%) 7 (27%) 2 (29%)
Complete remissions 63 (64%) 19 (86%) 29 (67%) 13 (50%) 2 (29%)
Concomitant CBF and APL patients
Patient characteristics Total (%) CD34– CD34+CD38–ALDHint CD34+CD38–ALDHhigh Dual ALDHhigh & ALDHint
(n=11) (n=6) (n=4) (n=0) (n=0)
Median Age 55 (Range: 21-70) 60 (Range: 21-70) 40 (Range: 31-65) NA NA
Male 2 (18%) 2 (33%) 0 (0%) NA NA
WBC>50,000/mm3 0 (%) NA NA NA NA
t(8;21)(q22;q22) 2 0 2 0 0 
inv (16) 2 0 2 0 0 
APL* 7 6 0 0 0 
Complete Remissions 11 (100%) 6 (100%) 4 (100%) NA NA
ALDH: aldehyde dehydrogenase; NA: not applicable; WBC: white blood count; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MPN: myeloid proliferative neoplasm;
FLAM: flavopiridol, cytarabine, mitoxantrone; CBF: core binding factor; APL: acute promyelocytic leukemia; *the most primitive leukemic phenotype detectable in one APL patient
was CD34+CD38+ALDHint.
Table 2. Characterization of the most immature phenotype present in the leukemia by CD34, CD38, and ALDH.
AML Subtype # % CD34+ *% CD34+ CD34+CD38–ALDHint CD34+CD38–ALDHhigh
CD38– ^%  %FISH+ ^% %FISH+
CD34– 22 0.52+0.08 100 0 NA 100 2.2±1.6
APL 7 0.15±0.04# 100 0 NA 100 0
CD34+CD38–ALDHint 43 26.1±4.1 45.3±4.5 65.1±3.4 69.4±13.6 1.7±0.5 2.9±1.8
CBF 4 13.8±7.7 22.4±9.1 78.1±5.6 98±0.3 3.8±3.5 0
CD34+CD38–ALDHhigh 26 25.2±4.6 43.1±5.9 0 NA 65.6±2.5 78±6.7
CD34+CD38– dual 7 21.2±16.9 40±8.7 34.4±3.3 94±4 40.2±5.2 92±5
ALDHint/ALDHhigh
AML: acute myeloid leukemia; ALDH: aldehyde dehydrogenase; int: intermediate expression; FISH: fluorescence in situ hybridization. CBF: core-binding factor; APL: acute promye-
locytic leukemia; *of total CD34+ cells, ^of total CD34+CD38– cells, #1 of 7 APL patients had 27.3% CD34+ cells and is not included in these data; NA: not applicable. 
Absence of detectable CD34+ AML cells is associated with
NPM1 mutations or APL
Of the 22 patients in NCT01349972 with < 1% CD34+ cells
in the MMNCs, 14 harbored NPM1 mutations compared to
8 of the 76 patients with CD34+ AML cells (Table 1; Online
Supplementary Figure S2A, S2B, P<0.001). Of the 12 patients
with NPM1 mutations as the sole abnormality, no CD34+
leukemia cells could be detected in 11 (Online Supplementary
Figure S2A) and one harbored CD34+ CD38–ALDHint leukemia
cells (Online Supplementary Figure S2B) (P<0.002). The only
two patients in the series with t(9;11) were among the other
8 non-NPM1-mutated patients in this CD34– group
(P<0.001), as were 4 patients with normal cytogenetics
(Online Supplementary Figure S2A). Only one CD34– patient
harbored poor-risk cytogenetics, and 3 of the CD34– NPM1-
mutated patients also manifested FLT3-ITD mutations
(Online Supplementary Figure S2A). Of the 8 CD34+NPM1-
mutated patients, 6 had a predominant population of
CD34+CD38–ALDHint (5 had additional detectable mutations)
and 2 (both with complex cytogenetics) had
CD34+CD38–ALDHhigh leukemia cells (Online Supplementary
Figure S2B).
Of the 7 APL patient specimens available for study, 6 also
had < 1% (0.15+0.04) CD34+ cells (Tables 1, 2). These 6
patients showed exactly the same pattern as the other AMLs
with <1% CD34+: i.e., the CD34+ cells were exclusively
CD38–ALDHhigh and lacked the t(15;17) by FISH (Table 2).
CD34+ cells comprised 27.3% of the MMNCs in the other
APL patient (Table 2); very few (0.9%) of the CD34+ cells
from this patient were CD38–, and they all lacked t(15;17) by
FISH. In contrast, the CD34+CD38+ cells did harbor the
translocation.
CD34+CD38–ALDHhigh leukemia cells are associated with
poor-risk AML
Of the 26 patients in NCT01349972 displaying a predom-
inant CD34+CD38–ALDHhigh leukemic population, 17 had
poor-risk cytogenetics and an additional 4 patients had FLT3-
ITD mutations (Table 1). All 7 of the patients with dual
CD34+CD38–ALDHint and CD34+CD38– ALDHhigh leukemia
populations also harbored poor-risk cytogenetics: 4 had high-
ly complex cytogenetic changes, two del 7q, and one del 5q
(Table 1). Thus, 28/33 (85%) patients with
CD34+CD38–ALDHhigh AML cells harbored poor-risk genetic
markers, while only 4 of the 22 (18%) patients with <1%
CD34+ cells and 16 out of 43 (37%) patients with predomi-
nant CD34+CD38–ALDHint populations harbored poor-risk
cytogenetics or FLT3-ITD mutations (P<0.0001). The patients
with CD34+CD38–ALDHhigh AML cells were also more likely
to have AML arising out of myelodysplastic syndrome or
myeloproliferative disease (18/33, 55%) than the
CD34+CD38–ALDHint and CD34– groups (21/65, 32%,
P=0.04).
The leukemias’ most primitive hematopoietic cell 
phenotype correlates with outcomes
Not surprisingly, given the strong association with poor-
risk genetics, patients harboring CD34+CD38–ALDHhigh
leukemic populations displayed relative drug resistance.
There was a significantly lower CR rate for patients harbor-
ing CD34+CD38–ALDHhigh leukemic populations when com-
pared to patients with CD34+CD38–ALDHint or no CD34+
cells AML cells (Table 3, P=0.007). The CR rates for the
patients with CD34+CD38–ALDHhigh leukemic populations
were similar with FLAM (11/24, 46%) and 7+3 (4/9, 44%).
However, there was a trend for more CRs on the FLAM arm
(36/45, 80%) than on the 7+3 arm (12/20, 60%) in the other
65 patients (P=0.1).
We next studied if the most immature phenotype present
in the leukemia also showed a correlation with survival. OS
was significantly different according to most immature
leukemia phenotype present in the leukemia (P=0.02, Table
3, Figure 4A), with patients harboring CD34+CD38–ALDHhigh
AML cells demonstrating the worst OS. There was also a sig-
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Figure 2. Prominent ALDHint population of CD34+CD38– cells from a patient with FLT3-ITD AML. (A) Representative flow cytometric staining pattern of ALDH activity
by side scatter (SSC) is displayed for CD34+CD38– cells isolated from patient. (B) FLT3-ITD status of isolated cell fractions. The CD34+CD38–ALDHint population (oval)
harbored the FLT3-ITD mutation, while the CD34+CD38–ALDHhigh cells (square) exclusively displayed the 330bp wild-type gene. 
A B
nificant difference in EFS according to the most primitive
leukemia phenotype (P<0.001, Table 3, Figure 4B). The EFS
probability at 1-year was 61% (95% CI, 41-90%), 45% (95%
CI 29-69%), and 19% (95% CI 8-47%) for patients without
detectable CD34+ leukemia cells and those with
CD34+CD38–ALDHint and CD34+CD38–ALDHhigh leukemia
cells, respectively (P<0.001). 
As others have found a strong correlation between just
leukemic CD34+CD38– cell numbers (without using ALDH
expression) at diagnosis and outcome,7,15 we analyzed the
prognostic impact of total CD34+CD38–numbers. There was
a trend for total CD34+CD38– cell numbers at diagnosis to
correlate with outcome. For patients with detectable CD34+
AML cells in trial NCT01349972, CD34+CD38– cells repre-
sented 5.6+1.5% of the MMNCs for those who entered a CR
compared to 11+3% in those who did not (P=0.08, t-test). Of
those patients with < 5% CD34+CD38– cells, 23% remained
event-free compared to 9.5% with > 5% CD34+CD38– cells
(P=0.2, Fisher's exact test). The mean frequency of
CD34+CD38– cells was the same in both the ALDHint and
ALDHhigh groups at 7.6+1.8% and 7.5+2.5%, respectively.
The type of postremission therapy was not specifically
mandated on this trial, and many of the patients went onto
alloBMT (Table 3). AlloBMT was very effective in all patients
in NCT01349972, regardless of their most primitive
leukemia phenotype. Of the patients with ALDHhigh leukemia
cells, 8/15 who achieved a CR underwent alloBMT in CR1
and 5 remain alive and disease-free (Table 3). Similarly, 16 of
the CD34+CD38–ALDHint and 6 of the CD34– patients under-
went alloBMT in CR1, and 7 and 5 patients remain alive and
disease-free, respectively (Table 3, P=0.2). In contrast, the
outcomes of the patients who did not receive alloBMT in
CR1, with most receiving cytarabine-based consolidation
therapy, differed significantly by the most primitive pheno-
type present in leukemia cells. Seven patients with
CD34+CD38–ALDHhigh leukemia cells did not undergo
alloBMT in CR1, and all relapsed including 3 with normal
cytogenetics and wild-type FLT3/NPM1 (Table 3). In con-
trast, 4/13 (3/9 with normal cytogenetics and wild-type
FLT3/NPM1) patients with CD34+CD38–ALDHint leukemia
cells and 7/13 (1 of 2 with normal cytogenetics and wild-type
FLT3/NPM1) CD34– patients who did not undergo alloBMT
remain alive and disease-free in CR1 (Table 3, P=0.06).
Discussion
The failure of CRs to reliably translate into cures in AML35,36
can be explained by the LSC paradigm. However, the true
clinical relevance of LSCs remains the focus of considerable
debate.3-20,37 Several groups have shown that CD34+CD38–
leukemia cell numbers present at diagnosis have strong prog-
nostic significance, providing support for a clinical relevance
for LSCs.7,15 Patients with increased numbers of CD34+CD38–
at diagnosis in clinical trial NCT01349972 showed a trend
toward worse outcomes. Our inability to show a stronger
clinical correlation between CD34+CD38– leukemia cell num-
bers at diagnosis and outcome may relate to the exclusion of
favorable-risk cytogenetic-risk groups from the study. We
also did not use the same methodology as others who
showed a stronger correlation; we analyzed only total
CD34+CD38– numbers, while others further refined the
CD34+CD38– subset to include the expression of leukemic
stem cell associated markers7 or CD123.15 We did find that
the most immature hematopoietic cellular phenotype pres-
ent in leukemia cells was heterogeneous, ranging from
CD34– to that of primitive HSCs (i.e., CD34+CD38–ALDHhigh),
but was relatively consistent across AML risk groups.
Perhaps most importantly, the strong association between
the leukemic clone’s most immature phenotype and out-
come in this prospective patient cohort supports further test-
ing of this clinical biomarker in future studies.
The vast majority of AML patients (80/109) in our series
harbored CD34+CD38– leukemia cells, as initially reported
by Lapidot et al.1 Moreover, we confirmed our prior data13
that the majority of non poor-risk AMLs, including all of the
CBF patients, harbored CD34+CD38– leukemia cells that
could be separated from normal HSCs by their lower
ALDH activity. However, 33 out of 98 (34%) of patients
from NCT01349972 harbored CD34+CD38–ALDHhigh
leukemia cells. This group of patients was more likely to
harbor poor-risk cytogenetics or FLT3-ITD mutations, and
had a statistically lower chance of achieving CRs than the
other AML patients. Importantly, the presence of
CD34+CD38–ALDHhigh leukemia cells was associated with a
significantly lower EFS and OS, even when no unfavorable
genetic or cytogenetic abnormalities could be identified.
Even though patients with CD34+CD38–ALDHhigh LSCs did
J.M. Gerber et al.
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Table 3. Clinical outcomes of patients in NCT01349972 by leukemia’s most primitive hematopoietic cellular phenotype.
CD34+CD38–ALDHhigh CD34+CD38–ALDHint CD34– P*
(including dual) (n=43) (n=22)
(n=33)
Complete remission 15/33 (45%) 29/43 (67%) 19/22 (86%) 0.007
Median OS (months) 9.4 (95% CI: 6-36) 18.7 (95% CI: 13-36) Not reached 0.02
HR – 1.3 (95% CI: 0.7-1.4) HR – 1 HR - 0.4 (95% CI: 0.2–1)
Median EFS (months) 2.2 (95% CI: 2-6) 11.3 (95% CI, 4-36) 13 (95% CI: 4-36) 0.001
HR = 2.2 (95% CI: 1.2-3.9) HR - 1 HR - 0.6 (95% CI: 0.3-1.3)
AlloBMT in CR1 8/15 (53%) 16/29 (55%) 6/20 (30%)
Continuously EF 5/8 (63%) 7/16 (44%) 5/6 (83%) 0.2
Median EFS (months) Not reached Not reached 23.1 (95% CI: 23 – 35)
No BMT in CR1 7/15 (47%) 13/29 (45%) 13/20 (65%)
Continuously EF 0/7 4/13 (31%) 7/13 (54%) 0.06
Median EFS (months) 4.6 (95% CI: 3 – 32) 11.9 (95% CI: 5 – 32) Not reached
ALDH: aldehyde dehydrogenase; int: intermediate expression; EF: event (relapse or death)-free; EFS: event-free survival; OS: overall survival; alloBMT: allogeneic bone marrow trans-
plantation; CR1: first complete remission; HR: hazard ratio; CI: confidence interval; *P values for Fisher’s exact tests. 
poorly overall, 5/8 of those patients who got to alloBMT
remain alive and disease-free. Several groups have also
described ALDHhigh LSCs in a fraction of AML patients who
appeared to have a worse prognosis.8,17-20 
No CD34+ leukemia cells could be detected in 22/98
patients from NCT01349972. As others have also
described,7,16,34 the CD34+ cells in these patients represented
<1% of the cells at diagnosis, were exclusively
CD38–ALDHhigh, and lacked the leukemic mutation. Thus, the
CD34+ cells in such patients likely represented residual nor-
mal HSCs. NPM1 mutations were detected in 14 (64%) of
the 22 AML patients who lacked detectable CD34+ cells, and
11/12 AML patients with NPM1 mutation as a sole abnor-
mality were in this group. No CD34+ cells were detected in
6/7 APL patients, as others have also found.38 The one APL
patient in this series with CD34+ AML cells only had the
t(15;17) detected in the CD34+CD38+ cells. Other groups
have reported that CD34 expression is a bad prognostic fac-
tor for both NPM1-mutated AMLs39 and APLs;40-42 the small
numbers of these patients in our cohort may have hindered
demonstrating similar statistical significance. 
The phenotype of the LSCs in NPM1-mutated AML has
been somewhat controversial. Two other groups also found
that most NPM1-mutated AMLs were CD34–, with the
CD34+ cells lacking leukemia mutations.4,16 However, Martelli
et al. found that the NPM1 mutation was present in
CD34+CD38– cells, and these cells generated AML in immun-
odeficient mice.43 Interestingly, CD34+ cells represented
>1.5% of the MMNCs in all the NPM1-mutated AMLs trans-
planted into mice in that report.43We also found the mutation
in the CD34+CD38– cells from all 8 NPM1-mutated AML
patients with >1% CD34+ MMNCs. Of note, 7 of these
patients had cytogenetic or FLT3-ITD mutations in addition
to NPM1. Thus, it appears that the most immature leukemic
cell in NPM1-mutated AMLs can be either CD34+ or CD34–;
it is possible that the differences can be explained by the fact
that Martelli et al. did not perform immunodeficient mouse
transplants with any of the 18 patients in their series harbor-
ing < 1% CD34+ cells.43 
Despite our inability to detect AML cells by PCR in the
small population of CD34+ cells present in the diagnostic
marrows of the CD34– AMLs, a very small number (2.2%) of
CD34+CD38–ALDHhigh cells had the FISH marker that charac-
terized the AML (Table 2). Zeijlemaker et al. recently suggest-
ed that although the vast majority of AML patients with <
1% CD34+ cells in their diagnostic marrow lacked CD34+
AML cells, a small number did harbor neoplastic CD34+
cells.21 It is similarly possible that CD34+CD38–ALDHhigh AML
cells may be present at very low levels in the patients whose
leukemias’ most immature phenotype appeared to be
CD34+CD38–ALDHint; however, based on the low FSC/SSC
of these CD34+CD38–ALDHhigh cells , we believe that these
small leukemic populations by FISH represent flow sorting
contamination. We also previously found that the
CD34+CD38–ALDHhigh cells present in AMLs harboring large
CD34+CD38–ALDHint populations only produced normal
hematopoiesis when transplanted into immunocompro-
mised mice.13 Importantly, the phenotype of the most primi-
tive hematopoietic cells found to harbor predominately
leukemia-specific mutations correlated with AML risk
groups and outcomes.
Our data raise the possibility that the most immature phe-
notype present in leukemia may be a function of the stage of
hematopoietic differentiation at which the leukemogenic
mutation develops. Those AMLs harboring leukemia cells
sharing a phenotype with primitive normal HSCs
(CD34+CD38–ALDHhigh) had the worst prognosis, while CBF
and intermediate-risk AMLs’ most primitive phenotype was
that of more differentiated hematopoietic progenitors
(CD34+CD38–ALDHint). The most immature hematopoietic
phenotype found in the most favorable-risk AMLs, APLs and
those with NPM1-mutations as sole abnormalities, expressed
even more differentiated phenotypes: CD34+CD38+ and
CD34–CD38+. 
These findings suggest that the leukemia clones’ most
primitive hematopoietic cellular phenotype might serve as a
biomarker for risk-stratifying patients at diagnosis. About 30-
40% of AML patients lack any cytogenetic or usual genetic
prognostic factors,44 and even when present such prognostic
factors may not be available for days or weeks. The most
immature phenotype present in leukemia cells can be readily
determined in essentially all patients by flow cytometry
within hours of diagnosis. Rapid risk-stratification may be
particularly useful for patients harboring
CD34+CD38–ALDHhigh leukemia cells, which appear to iden-
tify high-risk patients often refractory to induction
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Figure 3. Prominent ALDHhigh populations of CD34+CD38– cells. (A) Representative flow cytometric staining pattern of ALDH activity by side scatter (SSC) is displayed
for CD34+CD38– cells isolated from patient. The CD34+CD38-ALDHhigh cells represented essentially all of the total CD34+CD38- cells. (B) FLT3-ITD status of isolated
cell fractions. The CD34+CD38-ALDHhigh population harbored the FLT3-ITD mutation. (C) Representative flow cytometric staining pattern of ALDH activity by side scatter
(SSC) is displayed for CD34+CD38– cells isolated from a patient with dual CD34+CD38–ALDHint and CD34+CD38–ALDHhigh populations.
A B C
chemotherapy.  Although the phenotype of
CD34+CD38–ALDHhigh leukemia cells is the same as normal
HSCs, the flow cytometric pattern of the
CD34+CD38–ALDHhigh population at AML diagnosis allows
the primitive leukemic phenotype to be clearly distinguished
from HSCs even in the absence of cytogenetic or genetic
markers. The ALDHhigh cells represent the vast majority of the
CD34+CD38– cells and had higher FSC/SSC at diagnosis
when leukemic (Figures 3A, Table 2), while the low FSC/SSC
ALDHhigh HSCs represented only a very small percentage (on
average 1-2%) of the total CD34+CD38– cells (Figure 2A,
Table 2). Others have published similar findings.7 Should
studies confirm the adverse prognosis of a
CD34+CD38–ALDHhigh leukemia phenotype, rapid identifica-
tion of such patients could allow them early access to clinical
trials studying novel induction approaches. Moreover, a
CD34+CD38–ALDHhigh leukemic phenotype could be used to
guide patients toward alloBMT when no prognostic cytoge-
netic or genetic abnormalities are present. 
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